An analysis of the Michaelis-Menten pharmacokinetics of phenytoin in epileptic Indonesian adults

被引:1
作者
Sumarno [1 ]
Kusumastuti, Kurnia [2 ,3 ]
Khotib, Junaidi [1 ]
机构
[1] Univ Airlangga, Dept Pharm Practice, Fac Pharm, Gedung Nanizar Zaman Joenoes, Surabaya, East Java, Indonesia
[2] Univ Airlangga, Fac Med, Dept Neurol, Surabaya, Indonesia
[3] Dr Soetomo Hosp, Surabaya, Indonesia
来源
PHARMACY EDUCATION | 2023年 / 23卷 / 04期
关键词
Epilepsy; Michaelis-Menten; Phenytoin; Seizure;
D O I
10.46542/pe.2023.234.311315
中图分类号
G40 [教育学];
学科分类号
040101 ; 120403 ;
摘要
Background: Phenytoin metabolism has been shown to vary in different ethnic groups. Therefore, the authors studied phenytoin pharmacokinetics in Indonesian adult patients with epilepsy. Objective: The purpose of this study was to determine and analyse the pharmacokinetic parameters of Michaelis Menten Vmax (maximum velocity) and Km (the Michaelis constant) of phenytoin in adult epileptic patients. Method: Twelve adult epileptic patients were chosen on the basis that they had two reliable steady-state phenytoin serum levels at two different daily doses and they required an additional adjustment of phenytoin dosage monotherapy. Result: The Vmax and Km values for adult epileptic patients respectively, ranged from 3.78 to 9.65 mg/kg/day and from 0.71 to 5.58 mg/L and there was no correlation with age and weight (p > 0.05). The Vmax and Km values have shown individual variability. Conclusion: The optimal adjustment of phenytoin dose individually in adult epileptic patients based on Vmax and Km parameters needs to be done to get the desired steady-state level according to the clinical response.
引用
收藏
页码:311 / 315
页数:5
相关论文
共 18 条
[1]   Estimation of Phenytoin Pharmacokinetic Parameters in Saudi Epileptic Patients [J].
Alqahtani, Saeed ;
Alzaidi, Thuraya ;
Alotaibi, Mashal ;
Alsultan, Abdullah .
PHARMACOLOGY, 2019, 104 (1-2) :60-66
[2]  
BAUER L.A., 2008, Applied Clinical Pharmacokinetics, P485
[3]  
Chanruang A., 2021, International Journal of Pharmacy and Pharmaceutical Sciences, V13, P47, DOI [10.22159/ijops.2021v13i1.37178, DOI 10.22159/IJOPS.2021V13I1.37178]
[4]   CYP2C9☆1B Promoter Polymorphisms, in Linkage with CYP2C19☆2, Affect Phenytoin Autoinduction of Clearance and Maintenance Dose [J].
Chaudhry, Amarjit S. ;
Urban, Thomas J. ;
Lamba, Jatinder K. ;
Birnbaum, Angela K. ;
Remmel, Rory P. ;
Subramanian, Murali ;
Strom, Stephen ;
You, Joyce H. ;
Kasperaviciute, Dalia ;
Catarino, Claudia B. ;
Radtke, Rodney A. ;
Sisodiya, Sanjay M. ;
Goldstein, David B. ;
Schuetz, Erin G. .
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2010, 332 (02) :599-611
[5]   Impact of Genetic Polymorphisms on Phenytoin Pharmacokinetics and Clinical Outcomes in the Middle East and North Africa Region [J].
Dagenais, Renee ;
Wilby, Kyle John ;
Elewa, Hazem ;
Ensom, Mary H. H. .
DRUGS IN R&D, 2017, 17 (03) :341-361
[6]   PHENYTOIN DISPOSITION AND TOXICITY - ROLE OF PHARMACOGENETIC AND INTERETHNIC FACTORS [J].
EDEKI, TI ;
BRASE, DA .
DRUG METABOLISM REVIEWS, 1995, 27 (03) :449-469
[7]   Evidence-Based Guideline: Treatment of Convulsive Status Epilepticus in Children and Adults: Report of the Guideline Committee of the American Epilepsy Society [J].
Glauser, Tracy ;
Shinnar, Shlomo ;
Gloss, David ;
Alldredge, Brian ;
Arya, Ravindra ;
Bainbridge, Jacquelyn ;
Bare, Mary ;
Bleck, Thomas ;
Dodson, W. Edwin ;
Garrity, Lisa ;
Jagoda, Andy ;
Lowenstein, Daniel ;
Pellock, John ;
Riviello, James ;
Sloan, Edward ;
Treiman, David M. .
EPILEPSY CURRENTS, 2016, 16 (01) :48-61
[8]  
Horn J. R., 2021, Basic & Clinical Pharmacology, V15th, P1206
[9]  
ISMAIL R, 1990, J CLIN PHARM THER, V15, P411
[10]   Therapeutic drug monitoring in epilepsy clinic: a multi-disciplinary approach [J].
Lertsinudom, Sunee ;
Chaiyakum, Aporanee ;
Tuntapakul, Supinya ;
Sawanyawisuth, Kittisak ;
Tiamkao, Siriporn ;
Tiamkao, Somsak .
NEUROLOGY INTERNATIONAL, 2014, 6 (04) :83-85